利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

73 条记录 (耗时 0.057 秒)

    Regulated Stop Codon Readthrough
    3.
    发明申请
    Regulated Stop Codon Readthrough 审中-公开
    监管停止密码子阅读

    公开(公告)号：US20070224635A1

    公开(公告)日：2007-09-27

    申请号：US10587804

    申请日：2005-01-28

    申请人： Thomas Bouquin

    发明人： Thomas Bouquin

    IPC分类号： C12Q1/02 ,  C07H15/00 ,  C07H21/00 ,  G01N33/53 ,  C12N5/00 ,  C12P21/00

    CPC分类号： C12N15/1086 ,  C07K2319/035 ,  C07K2319/40 ,  C07K2319/60 ,  C12N15/62 ,  C12N15/67 ,  G01N33/502

    摘要： Methods for screening or selecting cells expressing a polypeptide of interest, e.g. for selecting cells expressing a desired level of a polypeptidé of interest, for evaluating recombinant polypeptide expression in a population of cells, or for selecting cells expressing a polypeptide with a desired binding affinity to a ligand, as well as for producing a polypeptide of interest from a selected cell, where the cells comprise an expression cassette comprising a first polynucleotide encoding the polypeptide of interest, at least one stop codon downstream of the first polynucleotide, and a second polynucleotide encoding a cell membrane anchoring peptide, a reporter peptide or an epitope tag downstream of the stop codon, and where the cells are cultured in the presence of a termination suppression agent, in particular an aminoglycoside antibiotic, that results in regulated stop codon readthrough.

    摘要翻译： 用于筛选或选择表达目的多肽的细胞的方法，例如 用于选择表达期望水平的感兴趣多肽的细胞，用于评估细胞群体中的重组多肽表达，或用于选择表达具有对配体的所需结合亲和力的多肽的细胞，以及用于产生感兴趣的多肽 选择的细胞，其中细胞包含表达盒，其包含编码目标多肽的第一多核苷酸，第一多核苷酸下游的至少一个终止密码子，以及编码细胞膜锚定肽，报告肽或表位标签的第二多核苷酸 在终止密码子的下游，并且其中细胞在终止抑制剂（特别是氨基糖苷类抗生素）存在下培养，导致调节的终止密码子读取。

    Protein C or activated protein C-like molecules
    4.
    发明授权
    Protein C or activated protein C-like molecules 失效
    蛋白C或活化蛋白C样分子

    公开(公告)号：US07226999B2

    公开(公告)日：2007-06-05

    申请号：US11004111

    申请日：2004-12-03

    申请人： Kim Vilbour Andersen ,  Anders Hjelholt Pedersen ,  Per Ola Freskgaard

    发明人： Kim Vilbour Andersen ,  Anders Hjelholt Pedersen ,  Per Ola Freskgaard

    IPC分类号： A61K35/14 ,  A61K38/48 ,  C07K14/00

    CPC分类号： C12N9/6464 ,  C12Y304/21069

    摘要： The present invention relates to novel conjugates between polypeptide variants of protein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular, the present invention provides novel protein C conjugates having an increased resistance to inactivation by e.g. human plasma and α1-antitrypsin. Consequently, such conjugates have an increased in vivo half-life. Preferred examples include protein C conjugates, wherein at least one additional in vivo N-glycosylation site has been introduced. The conjugates of the invention are useful for treating a variety of diseases, including septic shock.

    摘要翻译： 本发明涉及蛋白质C的多肽变体与非多肽部分如PEG或糖部分之间的新型缀合物。 特别地，本发明提供了新的蛋白质C缀合物，其具有增强的抗失活能力。 人血浆和α1 - 抗胰蛋白酶。 因此，这种缀合物具有增加的体内半衰期。 优选的实例包括蛋白质C缀合物，其中已经引入至少一个额外的体内N-糖基化位点。 本发明的缀合物可用于治疗各种疾病，包括败血性休克。

    Factor vii or viia polypeptide variants
    7.
    发明申请
    Factor vii or viia polypeptide variants 有权
    因子vii或viia多肽变体

    公开(公告)号：US20060111282A1

    公开(公告)日：2006-05-25

    申请号：US10512754

    申请日：2003-04-29

    申请人： Jesper Haaning ,  Kim Andersen

    发明人： Jesper Haaning ,  Kim Andersen

    IPC分类号： A61K38/37

    CPC分类号： C12N9/6437 ,  A61K38/00 ,  C12Y304/21021

    摘要： The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma.

    摘要翻译： 本发明涉及因子VII（FVII）或因子VIIa（FVIIa）多肽的新型多肽变体，其中所述变体包含位置10和32的氨基酸取代，并且其中所述变体还包含共价连接到引入 位于Gla结构域之外的体内N-糖基化位点。 这样的多肽变体可用于治疗，特别是用于治疗各种凝血相关疾病如创伤。

    G-CSF polypeptides and conjugates
    8.
    发明申请
    G-CSF polypeptides and conjugates 审中-公开

    公开(公告)号：US20060084793A1

    公开(公告)日：2006-04-20

    申请号：US11196846

    申请日：2005-08-03

    申请人： Torben Nissen ,  Kim Andersen ,  Christian Hansen ,  Jan Mikkelsen ,  Hans Schambye

    发明人： Torben Nissen ,  Kim Andersen ,  Christian Hansen ,  Jan Mikkelsen ,  Hans Schambye

    IPC分类号： C07K14/54

    CPC分类号： A61K9/0019 ,  A61K38/00 ,  A61K47/42 ,  C07K14/535

    摘要： The invention relates to polypeptide conjugates comprising a polypeptide exhibiting G-CSF activity and having an amino acid sequence that differs from the amino acid sequence of human G-CSF in at least one specified introduced and/or removed amino acid residue comprising an attachment group for a non-polypeptide moiety, and having at least one non-polypeptide moiety attached to an attachment group of the polypeptide. The attachment group may e.g., be a lysine, cysteine, aspartic acid or glutamic acid residue or a glycosylation site, and the non-polypeptide moiety may e.g., be a polymer such as polyethylene glycol or an oligosaccharide. The conjugate has one or more improved properties such as increased biological half-life and reduced side effects.

    Polynucleotides encoding S99T interferon gamma polypeptide variants and means of expression
    9.
    发明申请
    Polynucleotides encoding S99T interferon gamma polypeptide variants and means of expression 失效
    编码S99T干扰素γ多肽变体的多核苷酸和表达手段

    公开(公告)号：US20050249703A1

    公开(公告)日：2005-11-10

    申请号：US11158848

    申请日：2005-06-22

    申请人： Anne Jensen

    发明人： Anne Jensen

    IPC分类号： A61K38/00 ,  C07K14/57 ,  C07H21/04 ,  C12N15/00 ,  C12N15/09

    CPC分类号： C07K14/57 ,  A61K38/00

    摘要： The present invention relates to novel interferon gamma polypeptide variants having interferon gamma (IFNG) activity, methods for their preparation, pharmaceutical compositions comprising the polypeptide variants and their use in the treatment of diseases, in particular for the treatment of interstitial pulmonary diseases, such as idiopathic pulmonary fibrosis. These novel polypeptide variants all comprise the substitution S99T as compared to the amino acid sequence of huIFNG or fragments thereof. By performing this mutation the naturally occurring N-glycosylation site present at position 97 is significantly better utilized. Preferably, the variants comprise further modifications, e.g. in order to increase the AUC of such variants when administered subcutaneously.

    摘要翻译： 本发明涉及具有干扰素γ（IFNG）活性的新型干扰素γ多肽变体，其制备方法，包含多肽变体的药物组合物及其在治疗疾病中的用途，特别是用于治疗间质性肺疾病，例如 特发性肺纤维化。 与huIFNG或其片段的氨基酸序列相比，这些新型多肽变体全部包含取代S99T。 通过进行该突变，存在于位置97处的天然存在的N-糖基化位点被显着地更好地利用。 优选地，变体包括进一步的修饰，例如。 以便在皮下施用时增加这些变体的AUC。

    Protein C or activated protein C-like molecules
    10.
    发明授权
    Protein C or activated protein C-like molecules 失效
    蛋白C或活化蛋白C样分子

    公开(公告)号：US06933367B2

    公开(公告)日：2005-08-23

    申请号：US09997623

    申请日：2001-11-29

    申请人： Kim Vilbour Andersen ,  Anders Hjelholt Pedersen ,  Per Ola Freskgaard

    发明人： Kim Vilbour Andersen ,  Anders Hjelholt Pedersen ,  Per Ola Freskgaard

    IPC分类号： C12N9/64 ,  A61K35/14 ,  A61K38/48 ,  C07K14/00

    CPC分类号： C12N9/6464 ,  C12Y304/21069

    摘要： The present invention relates to novel conjugates between polypeptide variants of protein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular, the present invention provides novel protein C conjugates having an increased resistance to inactivation by e.g. human plasma and α1-antitrypsin. Consequently, such conjugates have an increased in vivo half-life. Preferred examples include protein C conjugates, wherein at least one additional in vivo N-glycosylation site has been introduced. The conjugates of the invention are useful for treating a variety of diseases, including septic shock.

    摘要翻译： 本发明涉及蛋白质C的多肽变体与非多肽部分如PEG或糖部分之间的新型缀合物。 特别地，本发明提供了新的蛋白质C缀合物，其具有增强的抗失活能力。 人血浆和α1 - 抗胰蛋白酶。 因此，这种缀合物具有增加的体内半衰期。 优选的实例包括蛋白质C缀合物，其中已经引入至少一个额外的体内N-糖基化位点。 本发明的缀合物可用于治疗各种疾病，包括败血性休克。